A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents We are a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Our proprietary AOC platform is designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. Our pipeline currently has three programs in clinical development. Delpacibart zotadirsen, or del-zota (formerly AOC 1044) is a registrational study designed for people living with Duchenne muscular dystrophy, or DMD, and is currently in development with the ongoing Phase 2 EXPLORE44 Open-Label Extension (EXPLORE44-OLE™) study. Del-zota is specifically designed for people with mutations amenable to exon 44 skipping, or DMD44, and is the first of multiple AOCs we are developing for DMD.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -685M | -685M | -322M | -212M | -174M | -118M |
| EPS | $-4.97 | $-4.97 | $-2.89 | $-2.91 | $-3.34 | $-2.85 |
| Free Cash Flow | -664M | -664M | -308M | -123M | -139M | -99M |
| ROIC | -43.5% | -44.0% | -22.6% | -42.4% | -30.1% | -30.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.03 | 0.03 | 0.00 | 0.02 | 0.02 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -746M | -746M | -379M | -236M | -179M | -118M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -40.5% | -44.0% | -22.6% | -42.4% | -30.1% | -30.9% |
| Shares Outstanding | 138M | 138M | 112M | 73M | 52M | 41M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 15M | 38M | 101M | 150M | 191M | 304M | 559M | 559M |
| SG&A | 5.1M | 13M | 26M | 38M | 54M | 86M | 206M | 206M |
| EBIT | -17M | -44M | -118M | -179M | -236M | -379M | -746M | -746M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -25M | -44M | -118M | -174M | -212M | -322M | -685M | -685M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -17.9% | -14.4% | -30.9% | -30.1% | -42.4% | -22.6% | -44.0% | -43.5% |
| ROE | N/A | -14.5% | -30.9% | -30.1% | -42.4% | -22.6% | -44.0% | -40.5% |
| ROA | -25.5% | -13.3% | -27.6% | -27.2% | -33.8% | -20.6% | -38.9% | -35.0% |
| Cash Flow | ||||||||
| Op. Cash Flow | 2.5M | -37M | -95M | -136M | -119M | -301M | -650M | -650M |
| Free Cash Flow | 2.3M | -38M | -99M | -139M | -123M | -308M | -664M | -664M |
| Owner Earnings | 1.7M | -42M | -113M | -165M | -159M | -355M | -752M | -752M |
| CapEx | 235K | 1.1M | 3.7M | 2.8M | 4.2M | 7.1M | 13M | 13M |
| Maint. CapEx | 348K | 373K | 639K | 1.4M | 2.1M | 2.8M | 4.2M | 4.2M |
| Growth CapEx | 0 | 719K | 3.1M | 1.4M | 2.1M | 4.3M | 9.2M | 9.2M |
| D&A | 348K | 373K | 639K | 1.4M | 2.1M | 2.8M | 4.2M | 4.2M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 406K | 4.3M | 17M | 27M | 38M | 51M | 98M | 98M |
| Debt Repayment | 2.8M | 4.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -181M | -323M | -629M | -670M | -360M | -433M | -716M | -333M |
| Cash & Equiv. | 95M | 321M | 320M | 340M | 185M | 220M | 383M | 383M |
| Long-Term Debt | 1.8M | 1.8M | N/A | N/A | N/A | N/A | N/A | 49M |
| Debt/Equity | -0.12 | 0.02 | 0.03 | 0.02 | 0.02 | 0.00 | 0.03 | 0.03 |
| Interest Coverage | -2.3 | -211.9 | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -65M | 306M | 381M | 578M | 501M | 1.4B | 1.7B | 1.7B |
| Total Assets | 97M | 334M | 428M | 639M | 629M | 1.6B | 2.0B | 2.0B |
| Total Liabilities | 28M | 28M | 46M | 61M | 128M | 139M | 269M | 269M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -22M | -67M | -185M | -359M | -571M | -893M | -1.6B | -1.6B |
| Working Capital | 85M | 317M | 381M | 571M | 531M | 1.4B | 1.6B | 1.6B |
| Current Assets | 96M | 332M | 411M | 623M | 611M | 1.5B | 1.8B | 1.8B |
| Current Liabilities | 10M | 15M | 30M | 52M | 81M | 98M | 195M | 195M |
| Per Share Data | ||||||||
| EPS | -9.12 | -2.05 | -2.85 | -3.34 | -2.91 | -2.89 | -4.97 | -4.97 |
| Owner EPS | 0.05 | -0.88 | -2.72 | -3.16 | -2.19 | -3.18 | -5.46 | -5.46 |
| Book Value | -1.74 | 6.41 | 9.21 | 11.10 | 6.87 | 12.78 | 12.26 | 12.26 |
| Cash Flow/Share | 0.07 | -0.78 | -2.29 | -2.62 | -1.63 | -2.70 | -4.72 | -4.94 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 37.6M | 47.8M | 41.4M | 52.1M | 72.9M | 111.5M | 137.8M | 137.8M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.1 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -34.4% |
| Market Cap | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.9B |
| Avg. Price | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 14.02 |
| Year-End Price | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 14.02 |
Avidity Biosciences, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Avidity Biosciences, Inc. (RNA) has a 5-year average return on invested capital (ROIC) of -34.0%. This is below average and may indicate limited pricing power.
Avidity Biosciences, Inc. (RNA) has a market capitalization of $1.9B. It is classified as a small-cap stock.
Avidity Biosciences, Inc. (RNA) does not currently pay a regular dividend.
Avidity Biosciences, Inc. (RNA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Avidity Biosciences, Inc. (RNA) generated $-664 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Avidity Biosciences, Inc. (RNA) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
Avidity Biosciences, Inc. (RNA) reported earnings per share (EPS) of $-4.97 in its most recent fiscal year.
Avidity Biosciences, Inc. (RNA) has a return on equity (ROE) of -44.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Avidity Biosciences, Inc. (RNA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Avidity Biosciences, Inc. (RNA) has a book value per share of $12.26, based on its most recent annual SEC filing.